## Statement of unaudited financial results for the quarter ended 30 June 2020

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Particulars</th>
<th>3 months ended 30/06/2020</th>
<th>Corresponding 3 months ended in the previous year 30/06/2019</th>
<th>Year ended 31/03/2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Unaudited</td>
<td>Unaudited</td>
<td>Audited</td>
</tr>
<tr>
<td>1</td>
<td>Total income from operations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Net profit/ (loss) for the period from ordinary activities before tax</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Net profit/ (loss) for the period from ordinary activities after tax</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Total comprehensive income for the period after tax</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Equity Share Capital</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Reserves (excluding revaluation reserves as per balance sheet)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Basic and diluted earnings per share (of Rs. 2 each)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Notes:


2. The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Place: Bengaluru
Date: 10 August 2020

Gagandeep Singh Bedi
Managing Director
## AstraZeneca

**CIN:** L24231KA1979PLC003563  
**Address:** 4th Floor, 13th Crescent, Magadi Road, Bangalore, Karnataka - 560045  
**Phone:** +91 80 6774 8000, **Website:** www.astrazeneca.com/India

### 30th June, 2020 Consolidated Quarterly Results

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Description</th>
<th>30/06/2020* 3 Lakh</th>
<th>30/06/2019* 3 Lakh</th>
<th>31/03/2020* 3 Lakh</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Net Sales</td>
<td>19,622.56</td>
<td>20,755.05</td>
<td>84,479.70</td>
</tr>
<tr>
<td>2</td>
<td>Profit Before Tax</td>
<td>2,638.44</td>
<td>3,362.91</td>
<td>11,396.04</td>
</tr>
<tr>
<td>3</td>
<td>Profit Before Tax &amp; Depreciation</td>
<td>1,863.47</td>
<td>2,151.54</td>
<td>7,221.09</td>
</tr>
<tr>
<td>4</td>
<td>Total Income</td>
<td>1,936.93</td>
<td>1,927.72</td>
<td>6,728.92</td>
</tr>
<tr>
<td>5</td>
<td>Total Expenses</td>
<td>500.00</td>
<td>500.00</td>
<td>500.00</td>
</tr>
<tr>
<td>6</td>
<td>Profit Before Tax &amp; Depreciation (After Adjustments)</td>
<td>-</td>
<td>-</td>
<td>35,943.62</td>
</tr>
<tr>
<td>7</td>
<td>Net Profit After Tax &amp; Depreciation (After Adjustments)</td>
<td>7.45</td>
<td>8.61</td>
<td>28.88</td>
</tr>
</tbody>
</table>

**Notes:**

1. The results have been prepared in accordance with the Indian Accounting Standards (IndAS) prescribed by the Ministry of Corporate Affairs (MCA) and the Securities and Exchange Board of India (SEBI). The results for the quarter ended 30th June 2020 have been prepared in accordance with the IndAS 13 and IndAS 11. For more information, please visit www.nseindia.com and www.bseindia.com.

2. This information is subject to change. For the latest information, please refer to the company’s official website or the latest financial reports.

*Date: 10th March 2020*